| Aug 20 |
Cosmos Health Reports Q1 2024 Results: Continues to Deliver Strong Growth and Improved Performance with 18% YoY Revenue Increase and 39% Rise in Gross Profit
|
| Aug 8 |
Cosmos Health Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash; Enters $750M+ Market
|
| Aug 7 |
Cosmos Holdings reports FY results
|
| Aug 6 |
Cosmos Health Reports Full Year 2023 Results: Revenue Increases to $53.4M, or 6% YoY; Stockholders' Equity Remains Near Record Highs at $36M, or $2.25 per Share
|
| Jul 25 |
Cosmos Health Signs Distribution Agreement with ProMed Trading for Its Sky Premium Life Food Supplements in Qatar
|
| Jul 24 |
Cosmos Health Updates on Contract Manufacturing Division; Completes Phase I of Production Capacity Expansion, Positioned to Generate Over $10M in Annual Gross Profit at Full Capacity
|
| Jul 19 |
Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Rule
|
| Jul 18 |
Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units
|
| Jul 10 |
Cosmos Health Advances Commercialization of CCX0722 Weight Management Solution with Completion of Pilot Production and Scale-Up Phases; Significant Step Towards Entering $143Bn Global Market
|
| Jul 9 |
Cosmos Health's Cana Secures Contract Manufacturing Agreement with Australia's Humacology for up to 500,000 CBD Units Annually
|
